论文部分内容阅读
目的：研究肺癌组织中ｐ５３、ｐ１６、ｎｍ２３基因蛋白的表达。方法：应用免疫组化ＬＳＡＢ方法检测１２９例肺癌标本中ｐ５３、ｐ１６、ｎｍ２３基因蛋白的表达。结果：ｐ５３、ｐ１６、ｎｍ２３蛋白在肺癌中的阳性表达率分别为５２７％、４５７％、５５８％；３种蛋白阳性表达率与组织学分型无明显相关（Ｐ＞００５）；肺腺癌淋巴结转移阳性组ｐ５３蛋白阳性表达率显著高于淋巴结无转移组（Ｐ＜００５）；ｐ５３蛋白阳性表达组及ｐ１６蛋白阴性表达组的预后差（Ｐ＜００５）；ｎｍ２３蛋白表达与患者预后无关。结论：ｐ５３、ｐ１６蛋白异常表达可做为评估肺癌患者预后的有效指标；未能证实ｎｍ２３基因在肺癌中具转移抑制功能。
Objective: To study the expression of p53, p16 and nm23 protein in lung cancer. Methods: The expressions of p53, p16 and nm23 proteins in 129 lung cancer specimens were detected by immunohistochemical LSAB method. Results: The positive rates of p53, p16 and nm23 in lung cancer were 52.7%, 45.7% and 55.8% respectively. There was no significant correlation between the positive rate of p53 protein and histological type 05). The positive expression rate of p53 protein in lymph node metastasis positive group was significantly higher than that in lymph node non-metastasis group (P <005). The prognosis of p53 protein positive group and p16 protein negative expression group was poor (P <005) ); Nm23 protein expression has nothing to do with the prognosis of patients. Conclusion: Abnormal expression of p53 and p16 protein can be used as a good indicator to evaluate the prognosis of patients with lung cancer. The role of nm23 in lung cancer metastasis was not confirmed.